Canadian Meds |
Policy | Legal
Terms | Meds Index
In recent years a good range of powerful antibiotics with a broad spectrum of antimicrobial activity, providing an opportunity for monotherapy have been introduced in clinical practice. These antibiotics reduce the risk of adverse drug interactions, complications of therapy, reduces the average time of administration, facilitates the work of the medical staff and reduces the cost of treatment.
The list of requirements for antibacterial drugs for monotherapy aimed at eliminating infections severe includes a wide spectrum of antibacterial activity, covering the major pathogens (Enterobacteriaceae, Staphylococcus spp., Enterococcus spp., Pseudomonas aeruginosa, surgical infections and anaerobes ), stability to bacterial beta- lactamases, good penetration into tissue, ease of dosing and good tolerability. All the mentioned above has been implemented in Meropenem, a brand-new beta-lactam antibiotic.
Meropenem: indications for use
The first drug of this group, imipenem, was introduced in clinical practice in 1986. However, it lacked efficiency and therefore was used as a separate preparation along with a specific inhibitor of renal dehydropeptidase-cilastatin which has no antibacterial activity, but prevents inactivation of imipenem in the kidney.
Meropenem is used to treat severe infections , mainly hospital , especially when an unknown causative agent of the disease. Broad spectrum of activity and high bactericidal activity allow the use of meropenem as monotherapy (without potentially toxic aminoglycosides ) , even in the treatment of severe infections - in patients in intensive care, with agranulocytosis , immunodeficiency.
The new drug class, meropenem, was introduced in 1994. Meropenem is characterized by higher stability to the action of renal dehydropeptidase, and therefore does not require the simultaneous application of its type enzyme inhibitors cilastatin. Furthermore, meropenem, unlike imipenem, is not characterized by nephrotoxic properties.
The medication provides the broad spectrum antibacterial activity against bacterial agents. The medication is highly active against Gram-positive cocci ( streptococci , pneumococci , staphylococci metsitillinochuvstvitelnyh), the majority of Gram-negative bacteria (including Pseudomonas aeruginosa and atsinetobakter) and anaerobes (Gram-positive cocci, Bacteroides, Clostridium, actinomycetes). Carbapenems have moderate activity against enterococci and listeria, but not active against methicillin-resistant Staphylococcus, Mycoplasma and Chlamydia.
Meropenem is 5-10 times efficient in comparison with imipenem as for action on gram-negative bacteria and is slightly more effective against Gram-positive bacteria; anti-anaerobic activity of these drugs is about the same.
The high efficacy of meropenem in dosages of 500mg – 1mg on a daily basis as monotherapy demonstrated impressive results in treating pneumonia, complicated urinary tract infections, peritonitis, infection of skin and soft tissues, gynecological infections, sepsis. Meropenem, unlike imipenem, due to the lack of neurotoxic effects, is successfully used for the treatment of meningitis in children and adults. Meropenem, unlike imipenem, is well tolerated (the probability of side effects of the gastrointestinal tract and seizures is observed in a minority of cases).
Before you are appointed a Meropenem course, inform your doctor of any allergies to penicillin or cepholasporin-based preparations, the drug may provoke allergic reactions and/or unwanted side effects. Taking the drug is also not recommended for those individuals with brain disorders and those ones suffering from kidney and stomach diseases.
© 2003-2017 Rx Meds Canada . All Rights Reserved